Comparative Pharmacology
Head-to-head clinical analysis: ARIMIDEX versus CYTADREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIMIDEX versus CYTADREN.
ARIMIDEX vs CYTADREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aromatase inhibitor; inhibits conversion of androgens to estrogens by binding to aromatase enzyme, reducing estrogen levels in tissues.
Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone, thereby blocking adrenal steroidogenesis. It also inhibits aromatase, reducing estrogen synthesis.
1 mg orally once daily
200 mg orally once daily
None Documented
None Documented
Terminal elimination half-life ~50 hours (range 30-60 hours); supports once-daily dosing.
Terminal elimination half-life: 3–4 hours in adults with normal renal function; prolonged to 8–12 hours in end-stage renal disease.
Primarily hepatic metabolism via N-dealkylation and glucuronidation; ~80% excreted in feces, <10% unchanged in urine.
Renal: ~60% as unchanged drug; biliary/fecal: ~25% as metabolites; minor via respiration.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor